About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2

NCT01925118·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Seoul National University Hospital

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histologically confirmed malignant melanoma or renal cell carcinoma
At stage IV or relapse
At least one prior chemotherapy including targeted agents
At least one haploidential or partially matched-HLA donor
ECOG performance status 0-1
Age 18-75 years
Measurable lesion
Adequate bone marrow, liver, and renal functions

You may not be if

Chemotherapy within 4 weeks
Stem cell transplantation
Active CNS metastasis
Hypersensitivity to IL-2

The record

StatusTerminated

PhasePhase 2

Taking part9

StartedAug 2013

UpdatedApr 26, 2016

Conditions

Metastatic Malignant Melanoma and Renal Cell Carcinoma

Where1

Seoul National University Hospital
Seoul, South Korea

Clareo Health | Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2